LIVE
A long-acting 32-amino-acid synthetic analog of the pancreatic hormone amylin (CAS 1415456-99-3), developed by Novo Nordisk. Agonizes calcitonin and amylin receptors to enhance satiety and suppress glucagon, a mechanism complementary to GLP-1 action. Co-formulated with semaglutide as CagriSema — Novo Nordisk submitted an NDA to the FDA for the fixed-dose combination after Phase 3 REDEFINE-1 reported -20.4% body weight vs. placebo at 68 weeks in obesity without diabetes. Cagrilintide monotherapy remains investigational.
For research purposes only. Not medical advice.
NextGen Peptide currently lists Cagrilintide at $4.80/mg, the lowest indexed price across 17 tracked research peptide vendors.
Cagrilintide ranges from $4.80/mg to $18.00/mg across 33 listings from 17 research peptide vendors, normalized to USD per milligram and refreshed daily.
17 research peptide vendors currently list Cagrilintide on PeptideScouter, with 16 in stock right now. We track 33 active listings across size and kit variants.
Cagrilintide's CAS Registry Number is 1415456-99-3. It is also sold as SA-4C, Cagri, Cag.
